IntrinsicIntrinsic
← All summaries

Ernexa Therapeutics Inc.

ERNAW
Financials & Chart →

Business Summary

Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cells) therapy company focused on developing scalable, affordable, off-the-shelf cell therapies for cancer and autoimmune diseases. The company's business model revolves around the development of these novel cell therapies, leveraging in-licensed intellectual property and seeking strategic partnerships for co-development or out-licensing to expand developmental opportunities and raise non-dilutive capital. Revenue generation is currently limited, with no revenue recognized in the fiscal year ended December 31, 2025 .

The company's core business model is centered on the research and development of synthetic allogeneic iMSC therapies. Ernexa generates revenue primarily through licensing agreements and, in the past, through cell line customization fees. The company's income is currently transactional, as evidenced by the assignment of its sole revenue-generating customer contract to Factor Bioscience Limited in September 2024 . This assignment means future payments to Ernexa from this contract will be a percentage of what Factor Bioscience receives, specifically 30% of amounts from the customer if a sublicense is obtained, and 20% of amounts for customization activities .

Ernexa's lead product candidate is ERNA-101, which consists of allogeneic IL-7 and IL-15-secreting iMSCs. ERNA-101 is designed to utilize the intrinsic tumor-homing ability of MSCs to deliver pro-inflammatory factors directly to the tumor microenvironment, aiming to limit systemic exposure and potential toxicity while enhancing anti-cancer immune responses. The initial development focus for ERNA-101 is platinum-resistant ovarian cancer. Preclinical studies have shown ERNA-101 to reduce tumor growth and provide a statistically significant survival advantage in an ovarian cancer model compared to a control group. The company had a successful pre-Investigational New Drug (IND) meeting with the FDA in the fourth quarter of 2025, achieving regulatory alignment for its development approach .

Another product candidate under investigation is ERNA-201, which involves anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs for autoimmune disorders such as rheumatoid arthritis. MSCs are known for their ability to home to inflamed tissue and dampen inflammation, and ERNA-201 aims to enhance these anti-inflammatory and regenerative effects .

For the fiscal year ended December 31, 2025, Ernexa Therapeutics Inc. reported no revenue , a decrease from $582 thousand in 2024 . The company's gross profit was also $0 in 2025, down from $486 thousand in 2024 . Operating expenses totaled $9.319 million in 2025 , leading to a loss from operations of $9.319 million . The net loss for the year was $14.084 million , resulting in a diluted EPS of $(2.24) . As of December 31, 2025, the company had cash of $1.884 million and an accumulated deficit of $245.6 million . Total liabilities were $3.433 million , and total stockholders' equity was $2.401 million .

Comparing fiscal year 2025 to 2024, total revenue decreased from $582 thousand to $0 . Cost of revenues also decreased from $96 thousand to $0 . Research and development expenses decreased by approximately $0.448 million, from $4.604 million in 2024 to $4.156 million in 2025 . General and administrative expenses saw a significant decrease of approximately $7.969 million, falling from $13.132 million in 2024 to $5.163 million in 2025 . The company recognized a gain on lease termination of $1.576 million in 2024, with no similar transaction in 2025 . Interest expense decreased substantially from $6.752 million in 2024 to $27 thousand in 2025 .

During the fourth quarter of 2025, Ernexa had a successful pre-Investigational New Drug (IND) meeting with the FDA for ERNA-101, achieving regulatory alignment for its development approach . In October 2025, the company entered into a master services agreement with Cellipont Bioservices for cell and gene therapy development and manufacturing services, including a $0.1 million nonrefundable project initiation fee and monthly progress and milestone payments for ERNA-101 . The company also completed a private placement in 2025, raising $7.2 million in gross proceeds from the sale of common stock and pre-funded warrants . Additionally, Ernexa entered into a sublease termination agreement for its Somerville, Massachusetts facility, effective August 31, 2024, resulting in a gain on lease termination of approximately $1.6 million in 2024 .

Business Outlook

Ernexa Therapeutics Inc. expects to complete the Investigational New Drug (IND) enabling studies and IND submission for ERNA-101 in 2026, with a subsequent entry into a Phase I investigator-sponsored clinical trial anticipated in the second half of 2026 . The company has not provided specific revenue, margin, or EPS guidance for the upcoming period.

A major growth vector for Ernexa is the advancement of its lead product candidate, ERNA-101, in platinum-resistant ovarian cancer. The company's strategy is to leverage the intrinsic tumor-homing ability of iMSCs to deliver pro-inflammatory factors directly to the tumor microenvironment, aiming to unleash potent anti-cancer immune responses. Preclinical studies have shown promising results, including reduction of tumor growth and a statistically significant survival advantage in an ovarian cancer model . The successful pre-IND meeting with the FDA in Q4 2025 provides regulatory alignment for this development approach .

Another significant growth area is the investigation of ERNA-201, which involves anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs for autoimmune disorders like rheumatoid arthritis. This program aims to turbocharge the natural anti-inflammatory and regenerative effects of MSCs that home to inflamed tissue . Furthermore, Ernexa has been accepted into the Japan External Trade Organization acceleration program, which will provide expert-led mentoring and market-entry guidance focused on Japan's regulatory, clinical, and commercial landscape. This program also offers direct engagement opportunities with leading Japanese research and development organizations to explore potential collaborations across development, manufacturing, and clinical execution .

Operationally, Ernexa plans to rely on contract manufacturing relationships for any future products. In October 2025, the company entered into a master services agreement with Cellipont Bioservices for cell and gene therapy development and manufacturing services, including a $0.1 million nonrefundable project initiation fee and monthly progress and milestone payments for ERNA-101 . The company's general and administrative expenses decreased by approximately $8.0 million for the year ended December 31, 2025, primarily due to decreases in occupancy expense and professional fees .

Regarding capital allocation, Ernexa intends to use the net proceeds from the 2026 Offering, which generated approximately $9.6 million , to support the advancement of its development programs, working capital, and general corporate purposes . The company's 401(k) plan involves matching employee contributions at a rate of 100% of the first 3% and 50% of the next 2%, for a maximum company match of 4% .

The company explicitly flagged that it will require substantial additional capital to fund its operations and execute its business strategy, and there is no assurance that adequate capital will be raised on a timely basis, on favorable terms, or at all . If capital cannot be raised, the company may need to reevaluate planned operations, reduce expenses, or potentially cease operations . Unstable and unfavorable market and economic conditions, including economic downturns, increased inflation, rising interest rates, and geopolitical conflicts, may harm the company's ability to raise additional capital . The company has incurred significant losses since inception, with an accumulated deficit of approximately $245.6 million as of December 31, 2025 , and expects to continue incurring losses for the foreseeable future . The company's ability to utilize its net operating loss carryforwards and tax credit carryforwards may be subject to limitations due to "ownership change" rules under Section 382 and Section 383 of the Code .

Risk Factors

Ernexa Therapeutics Inc. faces several material risks, including the critical need for substantial additional capital to fund its operations, with no assurance of obtaining necessary financing on favorable terms or at all, which raises substantial doubt about its ability to continue as a going concern . The company has incurred significant losses since inception, with an accumulated deficit of approximately $245.6 million as of December 31, 2025, and expects these losses to continue, making it difficult to assess its prospects . A significant reliance on in-licensed intellectual property from Factor Limited means that failure to comply with license obligations or termination of the Factor L&C Agreement could substantially harm product development and the ability to form co-development strategic partnerships . The company's product development relies on novel, inherently risky technologies in the relatively new field of stem cell therapy, and efforts may not result in effective treatments, with regulatory approval processes being lengthy, time-consuming, and unpredictable . Intense competition and rapid technological change in the biotechnology and pharmaceutical industries mean competitors may develop more advanced, safer, or more effective therapies, adversely affecting Ernexa's financial condition . Negative public opinion and increased regulatory scrutiny surrounding stem cell therapy or human tissue use could damage public perception of its synthetic allogeneic iMSC product candidates or adversely affect business operations . The manufacture of biotechnology products is complex, and difficulties in production, scaling up, quality control, and compliance with cGMP regulations could lead to product recalls, production halts, and supply disruptions . There is a risk of future sales or other dilution of equity, which may adversely affect the market price of common stock, particularly given the contingent consideration agreement that could result in the issuance of additional common stock if market capitalization thresholds of $100 million or $200 million are met by April 26, 2026 . The company's failure to meet Nasdaq's continued listing requirements, specifically the minimum bid price of $1.00 per share, could result in delisting, and having effected a reverse stock split within the last 12 months, the company would not be eligible for a compliance period if it fails again . Furthermore, anti-takeover provisions of Delaware law and provisions in the company's charter and bylaws could make a third-party acquisition difficult . The company's ability to utilize its net operating loss carryforwards and tax credit carryforwards may be subject to limitations under Section 382 and Section 383 of the Code if an "ownership change" occurs . Extensive and costly government regulation, including lengthy and unpredictable FDA approval processes, could substantially harm the business if product candidates are not approved . Disruptions at the FDA and other government agencies due to funding shortages or other events could negatively impact the business . Non-compliance with environmental and health and human safety laws regulating hazardous materials could lead to substantial liabilities, fines, or penalties . Healthcare legislative reform measures, such as the Inflation Reduction Act of 2022, may have a material adverse effect on the business by curbing drug prices and affecting reimbursement . Finally, the patent position of biotechnology and pharmaceutical companies is highly uncertain, and if licensors are unable to obtain and maintain broad intellectual property protection, competitors could develop similar products, adversely affecting profitability .

Management Priorities

Management's message to shareholders conveys a focus on advancing its preclinical-stage synthetic allogeneic iMSC therapy, with a mission to transform the treatment of cancer and autoimmune disease through scalable, affordable, off-the-shelf cell therapies. The company explicitly states its expectation to complete IND-enabling studies and IND submission for ERNA-101 in 2026, followed by entry into a Phase I investigator-sponsored clinical trial in the second half of 2026 . Management also emphasizes actively seeking strategic partnerships to co-develop or out-license therapeutic assets and applying for research grants to expand developmental opportunities and raise non-dilutive capital . The two key strategic priorities for the period ahead appear to be the successful progression of ERNA-101 into clinical trials and the securing of additional capital and strategic collaborations to fund ongoing operations and development programs. Management acknowledges the substantial doubt about the company's ability to continue as a going concern due to insufficient capital to fund operations for the next 12 months, highlighting the critical need for additional financing through equity, debt, or strategic arrangements .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Objectives and Business Strategy
  2. [2] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  3. [3] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  4. [4] Item 7, MD&A — Revenue
  5. [5] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  6. [6] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  7. [7] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  8. [8] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  9. [9] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  10. [10] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
  11. [11] Item 7, MD&A — Liquidity and Capital Resources
  12. [12] Item 7, MD&A — Liquidity and Capital Resources
  13. [13] Item 8, Consolidated Balance Sheets
  14. [14] Item 8, Consolidated Balance Sheets
  15. [15] Item 7, MD&A — Cost of Revenue
  16. [16] Item 7, MD&A — Research and Development Expenses
  17. [17] Item 7, MD&A — General and Administrative Expenses
  18. [18] Item 7, MD&A — Gain on Lease Termination
  19. [19] Item 7, MD&A — Interest Expense
  20. [20] Item 1, Business — Supply and Manufacturing
  21. [21] Item 7, MD&A — 2025 Private Placement of Equity
  22. [22] Item 7, MD&A — Gain on Lease Termination
  23. [23] Item 7, MD&A — 2026 Public Offering
  24. [24] Item 7, MD&A — 2026 Public Offering
  25. [25] Item 13, Commitments and Contingencies — Retirement Savings Plan
  26. [26] Item 1A, Risk Factors — Risks Related to our Business and Industry
  27. [27] Item 1A, Risk Factors — Unstable and unfavorable market and economic conditions may harm our ability to raise additional capital.
  28. [28] Item 1A, Risk Factors — We have incurred significant losses since our inception and expect to continue to incur losses for the foreseeable future, which, together with our limited financial resources and substantial capital requirements, make it difficult to assess our prospects.
  29. [29] Item 1A, Risk Factors — Our ability to utilize our net operating loss carryforwards and tax credit carryforwards may be subject to limitations.
  30. [30] Item 1A, Risk Factors — We rely heavily on in-licensed intellectual property from Factor Limited. Loss of this license or termination of the Factor L&C Agreement could significantly harm our product development and ability to enter co-development strategic partnerships, materially impacting our business.
  31. [31] Item 1A, Risk Factors — Our product development relies on novel, inherently risky technologies. Synthetic mesenchymal stem cell therapy is a relatively new field, and our efforts may not result in effective treatments for human diseases.
  32. [32] Item 1A, Risk Factors — We are in an industry with intense competition and rapid technological change, and our competitors may develop therapies that are more advanced, safer, or more effective than any therapy we develop in the future, which may adversely affect our financial condition.
  33. [33] Item 1A, Risk Factors — Negative public opinion and increased regulatory scrutiny due to ethical and other concerns surrounding the use of stem cell therapy or human tissue may damage public perception of our synthetic allogeneic iMSC product candidates or adversely affect our ability to conduct our business.
  34. [34] Item 1A, Risk Factors — The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production.
  35. [35] Item 1A, Risk Factors — There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock.
  36. [36] Item 1A, Risk Factors — Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.
  37. [37] Item 1A, Risk Factors — Anti-takeover provisions of Delaware law and provisions in our charter and bylaws could make a third-party acquisition of us difficult.
  38. [38] Item 1A, Risk Factors — Disruptions at the FDA and other government agencies caused by funding shortages or other events or conditions outside of their control could negatively impact our business.
  39. [39] Item 1A, Risk Factors — If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  40. [40] Item 1A, Risk Factors — Healthcare legislative reform measures may have a material and adverse effect on our business, financial condition, results of operations, and prospects.
  41. [41] Item 1A, Risk Factors — If the licensors of our in-licensed technology are unable to obtain and maintain patent and other intellectual property protection, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to those derived from such intellectual property, and our ability to achieve profitability may be adversely affected.

Analysis on 5/21/2026